Biosyent (RX) AI Stock Analysis

• Market Cap: C$128.53M
• Dividend Yield: 1.74%
• Average Volume (3M): 5.67K
• Price to Earnings (P/E): 15.4
• Beta (1Y): 0.41
• Revenue Growth: 16.82%
• EPS Growth: 19.25%
• Country: CA
• Employees: 60
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.18
• Shares Outstanding: 11,475,447
• 10 Day Avg. Volume: 6,048
• 30 Day Avg. Volume: 5,666
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$13.00
• Price Target Upside: 16.07% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 76 Outperform
• Price Target: C$13.00 ▲(16.07% Upside)

Biosyent's overall stock score is driven by strong financial performance and positive earnings call highlights, including robust revenue and profit growth, dividend increases, and share buybacks. While technical analysis presents mixed signals, the company's solid valuation and strategic initiatives support a favorable outlook.

Positive Factors

Strong Financial Health

The company's low debt-to-equity ratio and strong cash flow growth indicate robust financial stability, allowing for strategic investments and resilience against market fluctuations.

Revenue and Profit Growth

Sustained revenue and profit growth across multiple segments underscores Biosyent's effective market strategies and product demand, enhancing long-term business prospects.

Product Leadership

Leading product positions like FeraMAX strengthen Biosyent's competitive edge and market presence, supporting sustained revenue streams and brand loyalty.

Negative Factors

Product Line Challenges

Underperformance in certain product lines like Combogesic may hinder overall growth and require strategic adjustments to align with market demands.

Trade Uncertainties

Ongoing trade uncertainties could impact supply chains and cost structures, posing risks to operational efficiency and profitability if tariffs are imposed.

Revenue Fluctuations

Fluctuations in sales like those seen with Inofolic indicate potential volatility in revenue streams, necessitating careful inventory and demand management.

Biosyent Business Overview & Revenue Model

Company Description

BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; and Proktis-M, a rectal suppository for the healing of the anus and rectum. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.

How the Company Makes Money

Biosyent generates revenue primarily through the sale of its prescription products to healthcare providers, hospitals, and pharmacies. The company operates a revenue model based on direct sales and partnerships with other pharmaceutical companies for the distribution of their products. Key revenue streams include the sale of proprietary drugs, royalties from licensed products, and potential milestones from collaboration agreements. Strategic partnerships with healthcare professionals and institutions also contribute to its earnings, as they help in expanding market reach and enhancing product visibility.

Biosyent Financial Statement Overview

Summary

Biosyent demonstrates strong financial health with robust profitability, low leverage, and effective equity utilization. The income statement highlights strong revenue and profit growth, while the balance sheet reflects stability with minimal debt. Although cash flow management shows room for improvement, the company's financial outlook remains positive and well-positioned for future growth.

Income Statement

Biosyent demonstrates strong profitability with consistently high gross and net profit margins. The gross profit margin for TTM (Trailing-Twelve-Months) is 78.5%, and the net profit margin is 20.4%, indicating effective cost management and solid profitability. Revenue growth is also impressive, with a TTM growth rate of 9.2% compared to the previous year. The EBIT and EBITDA margins are healthy, at 25.2% and 29.5% respectively, showing robust operational efficiency.

Balance Sheet

The balance sheet is strong with a low debt-to-equity ratio of 0.03, indicating low leverage and financial stability. The return on equity (ROE) is 21.7%, reflecting effective use of equity to generate profits. The equity ratio is high at 84.2%, underscoring a solid equity base. Overall, the company's financial position is stable with ample equity and minimal debt, although the slight decrease in cash reserves is noteworthy.

Cash Flow

Biosyent's cash flow performance is solid with a positive free cash flow, although the free cash flow has decreased by 45.6% in the TTM period. The operating cash flow to net income ratio of 0.89 indicates good cash conversion, while the free cash flow to net income ratio of 0.28 suggests some room for improvement in cash flow management. Despite the decrease in free cash flow, overall cash flow stability is maintained.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	38.28M	35.03M	31.59M	27.93M	28.62M	22.33M
Gross Profit	30.05M	27.86M	25.60M	22.86M	22.64M	17.42M
EBITDA	11.28M	10.43M	9.06M	7.96M	8.92M	5.84M
Net Income	7.82M	7.27M	6.46M	5.46M	6.28M	3.80M
Balance Sheet
Total Assets	42.76M	41.36M	41.53M	40.49M	37.17M	33.57M
Cash, Cash Equivalents and Short-Term Investments	17.40M	15.94M	26.19M	28.70M	28.21M	25.58M
Total Debt	990.22K	1.04M	1.22M	1.40M	1.56M	1.71M
Total Liabilities	6.75M	6.36M	6.77M	7.12M	5.61M	6.78M
Stockholders Equity	36.01M	35.00M	34.76M	33.36M	31.55M	26.80M
Cash Flow
Free Cash Flow	2.17M	3.99M	4.88M	4.43M	4.58M	6.72M
Operating Cash Flow	6.99M	8.66M	5.05M	4.95M	4.67M	6.89M
Investing Cash Flow	4.08M	3.29M	883.85K	-10.79M	-4.84M	3.39M
Financing Cash Flow	-7.19M	-7.83M	-5.78M	-4.37M	-2.08M	-3.37M

Biosyent Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 11.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RX, the sentiment is Negative. The current price of 11.2 is below the 20-day moving average (MA) of 11.41, below the 50-day MA of 11.65, and below the 200-day MA of 11.25, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 35.81 is Neutral, neither overbought nor oversold. The STOCH value of 28.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:RX.

Biosyent Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RX	―	C$128.53M	15.40	22.62%	1.74%	16.82%	19.25%
TH	―	―	―	―	―	5.24%	-7.99%
MDP	―	C$87.10M	65.69	1.88%	―	0.03%	-17.30%
CTX	―	C$8.86M	-6.80	-8.12%	―	20.33%	53.93%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HLS	―	C$175.14M	―	-20.58%	―	-1.42%	35.15%
AQS	―	C$663.17K	―	―	―	192.96%	42.59%

Biosyent Corporate Events

BioSyent Inc. Reports Strong Growth Amid Challenges

BioSyent Inc.’s recent earnings call painted a largely positive picture, underscored by robust revenue and profit growth across its business segments. The company reported consistent profitability and highlighted successful dividend and share buyback programs. Despite some underperforming product lines and ongoing trade uncertainties, the overall sentiment was optimistic, driven by strong performance and growth initiatives.

BioSyent Inc. Reports Robust Growth in Q2 and H1 2025 Financial Results

BioSyent Inc. reported strong financial results for Q2 and H1 2025, with total company sales increasing by 14% and 27% respectively compared to the previous year. Canadian Pharma sales grew by 9% in Q2, while International Pharma sales surged by 183%. The company’s net income after taxes rose by 28% in Q2, and EBITDA increased by 35%, reflecting improved profitability despite a tighter gross margin due to changes in product mix. The company also repurchased shares and declared dividends, indicating a commitment to shareholder value. BioSyent’s strategic focus on portfolio diversification and profitable growth positions it well for continued success.

The most recent analyst rating on (TSE:RX) stock is a Buy with a C$13.00 price target. To see the full list of analyst forecasts on Biosyent stock, see the TSE:RX Stock Forecast page.

BioSyent Declares Consistent Q3 2025 Dividend

BioSyent Inc. has announced a quarterly dividend of $0.05 per common share for the third quarter of 2025, consistent with the previous quarter. This decision reflects the company’s ongoing profitability and commitment to shareholder returns, while the discretion over future dividends remains with the Board of Directors.

The most recent analyst rating on (TSE:RX) stock is a Buy with a C$13.00 price target. To see the full list of analyst forecasts on Biosyent stock, see the TSE:RX Stock Forecast page.

BioSyent to Announce Q2 and H1 2025 Financial Results

BioSyent Inc. has announced that it will release its financial results for the second quarter and first half of 2025 on August 21, 2025, after market hours. This announcement is significant for stakeholders as it provides insights into the company’s financial health and operational performance, potentially impacting its market positioning and investor confidence.

The most recent analyst rating on (TSE:RX) stock is a Buy with a C$11.75 price target. To see the full list of analyst forecasts on Biosyent stock, see the TSE:RX Stock Forecast page.